HUMA - Humacyte, Inc.
IEX Last Trade
5.47
0.050 0.914%
Share volume: 163,226
Last Updated: Fri 27 Dec 2024 08:30:35 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$5.42
0.05
0.92%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | |
| Report Date | 2022-05-13 | 2022-08-12 | 2022-11-10 | 2023-03-24 | 2023-05-12 | 2023-08-14 | |
| Total revenue | 233.000 K | 1.301 M | 31.000 K | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 233.000 K | 1.301 M | 31.000 K | 0.000 | 0.000 | 0.000 | |
| 458.37% | -97.62% | -100.00% | nan% | nan% | |||
| Operating expenses | 21.996 M | 19.832 M | 23.525 M | 20.790 M | 22.512 M | 26.731 M | |
| Selling general and admin | 5.682 M | 5.180 M | 6.188 M | 5.833 M | 5.234 M | 6.191 M | |
| Research and development | 16.314 M | 14.652 M | 17.337 M | 14.957 M | 17.278 M | 20.540 M | |
| Total expenses | 21.996 M | 19.832 M | 23.525 M | 20.790 M | 22.512 M | 26.731 M | |
| -9.84% | 18.62% | -11.63% | 8.28% | 18.74% | |||
| Operating income | -21.763 M | -18.531 M | -23.494 M | -20.790 M | -22.512 M | -26.731 M | |
| Ebit | -21.763 M | -18.531 M | -23.494 M | -20.790 M | -22.512 M | -26.731 M | |
| Pretax income | -19.832 M | 36.868 M | -25.281 M | -3.720 M | -36.969 M | -22.706 M | |
| -285.90% | -168.57% | -85.29% | 893.79% | -38.58% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -19.832 M | 36.868 M | -25.281 M | -3.720 M | -36.969 M | -22.706 M | |
| 285.90% | -168.57% | 85.29% | -893.79% | 38.58% | |||
| Net income | -19.832 M | 36.868 M | -25.281 M | -3.720 M | -36.969 M | -22.706 M | |
| 285.90% | -168.57% | 85.29% | -893.79% | 38.58% |